NASDAQ$ANGO

AngioDynamics Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

AngioDynamics experienced revenue growth and gross margin improvement, but reported a net loss and adjusted loss per share.

AngioDynamics reported a 9.6% increase in net sales compared to the prior-year quarter, driven by Med Tech growth. However, the company reported a net loss of $7.0 million, or $0.18 per share, and an adjusted loss per share of $0.02. The gross margin increased by 120 basis points year over year.

  • Net sales increased by 9.6% compared to the prior-year quarter.
  • Gross margin improved by 120 basis points year over year.
  • GAAP loss per share was $0.18, and adjusted loss per share was $0.02.
  • The company commenced a limited market release of its AlphaVac Mechanical Thrombectomy device in September.

Headline financials

Total Revenue

$77M

Previous: $70.2M+9.6%
EPS (adj)

-$0.02

Previous: $0.02-200.0%
Gross Margin

52.1%

Previous: 50.9%+2.4%
Capital Expenditures

-$1.02M

Previous: -$1.82M+44.0%
Free Cash Flow

-$7.99M

Previous: -$6.09M-31.2%
Net Income

-$6.97M

Previous: -$4.27M-63.4%
Operating Income

-$8.1M

Previous: -$5.12M-58.1%
Gross Profit

$40.1M

Previous: $35.8M+12.2%
Cash & Equivalents

$35.5M

Previous: $47.9M-26.0%
Total Assets

$556M

Previous: $584M-4.8%
Stock-Based Comp

$2.43M

Previous: $1.86M+30.3%

Revenue & EPS history

AngioDynamics · Revenue · Quarterly

$77M

Q1 2022+9.6%vs Q1 2021
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Revenue by segment

AngioDynamics · $77M total across 2 segments · Q1 2022

  • Med Device
    $59.4M
  • Med Tech
    $17.6M

Forward guidance

The Company now expects its fiscal year 2022 net sales to be in the range of $310 to $315 million, an increase from its prior guidance of $305 to $310 million. The Company expects gross margin to be approximately 55.0% and adjusted earnings per share in the range of $0.00 to $0.05 as it continues to invest in new product launches to drive future growth.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-0.9%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-3.7%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+30.9%

Q2 2025

Best reaction

-26.2%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+5.0%-5.0%
Q2 2026-13.5%-25.5%-24.0%
Q1 2026+6.1%-0.2%+8.7%
Q4 2025-10.2%-9.8%-9.3%
Q3 2025+12.4%-3.6%-3.8%
Q2 2025+30.9%+32.6%+17.4%
Q1 2025-20.3%-23.1%-12.7%
Q4 2024+24.8%+21.1%+25.8%
Q3 2024+15.6%+14.6%+3.1%
Q2 2024-17.7%-20.1%-23.5%
Q1 2024-5.9%-7.2%-10.4%
Q4 2023-2.5%-3.8%-16.1%
Q3 2023-17.1%-23.3%-33.3%
Q2 2023+11.5%-1.0%-1.3%
Q1 2023-26.2%-38.0%-34.8%
Q4 2022+4.4%+6.4%+21.3%
Q3 2022+9.8%+7.2%-8.7%
Q2 2022-15.5%-15.5%-25.8%
Q1 2022+12.6%+17.8%+22.4%
Q4 2021-7.0%-8.6%-3.9%
Q3 2021+12.3%+11.1%+16.3%
Q2 2021+14.7%+14.2%+24.7%
Q1 2021+13.0%+7.8%-0.1%
Q4 2020-11.5%-11.8%-12.7%
Q3 2020-2.7%+2.3%-0.6%
Q2 2020-9.2%-11.3%-17.0%
Q1 2020-17.6%-17.6%-13.7%
Q4 2019+6.8%+6.2%-4.8%
Q3 2019-7.7%-8.2%-18.4%
Q2 2019+6.7%+6.7%+8.6%
Q1 2019-10.3%-12.9%-17.0%
Q4 2018-9.2%-7.8%-5.4%
Q3 2018+3.2%+8.9%+16.4%
Q2 2018-1.8%-0.1%+5.1%
Q1 2018-8.9%-9.1%-8.4%
Q4 2017-5.9%-3.5%+5.1%
Q3 2017+0.3%-1.3%-10.2%
Q2 2017+1.7%+3.2%-2.5%
Q1 2017-4.5%-0.1%-8.4%
Q4 2016+10.6%+14.1%+8.4%
Q3 2016-2.1%
Q2 2016-8.7%
Q1 2016-8.8%
Q4 2015-2.3%
Q3 2015-6.1%
Q2 2015-0.9%
Q1 2015+3.8%
Q4 2014-5.0%
Q3 2014-1.5%
Q2 2014+6.1%
Q1 2014+5.3%
Q4 2013+1.3%
Q3 2013-7.4%
Q2 2013-2.4%
Q1 2013-8.8%
Q4 2010-0.9%
Q4 2012+4.0%
Q3 2011-1.3%
Q3 2012-1.3%
Q2 2012-5.7%
Q2 2011-5.7%
Q1 2011+3.5%
Q4 2011+3.5%
Q1 2012+3.5%
Q3 2010+0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro